Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive–compulsive disorder
Authors:
- Darin D. DoughertyDDDarin D. Dougherty
- Mariko JamesonMJMariko Jameson
- Thilo DeckersbachTDThilo Deckersbach
- Rebecca LohRLRebecca Loh
- Johanna Thompson-HollandsJTJohanna Thompson-Hollands
- Michael JenikeMJMichael Jenike
- Nancy J. KeuthenNKNancy J. Keuthen
- 1 November 2009
- journal article
- research article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 24 (6) , 306-311
Abstract
This study sought to investigate the efficacy of escitalopram at different dosages for the treatment of obsessive-compulsive disorder (OCD). Thirty individuals were enrolled in a 16-week, open-label trial of escitalopram and randomly assigned to the 20 or 30 mg study arm. Study measures assessing OCD symptoms, anxiety, depression, and quality of life were administered at baseline and weeks 2, 4, 8, 12, and 16. For the 23 study completers, pretreatment and posttreatment analyses revealed significant improvements (P<0.05) on clinician-rated and self-rated measures of OCD symptoms, quality of life, anxiety, and depression. Approximately half of the sample (n = 12) satisfied full medication response criteria and less than one-quarter (n = 5) were partial medication responders. Intention-to-treat analyses showed similar improvements (P<0.05) on all study measures. At study completion, a superior responder rate and more improvement on the Yale-Brown Obsessive Compulsive Scale (P<0.05) was reported for those in the 30 versus 20 mg study arm. The difference between the two groups, however, disappeared when initial differences in baseline depression and anxiety scores were used as analysis covariates. These results suggest that the 30 mg (vs. 20 mg) dose of escitalopram may provide a superior reduction in OCD symptoms for those sufferers with comorbid depression and/or anxiety.Keywords
This publication has 11 references indexed in Scilit:
- Obsessive-Compulsive Disorder: An Open-Label Pilot Trial of EscitalopramCNS Spectrums, 2007
- Escitalopram prevents relapse of obsessive-compulsive disorderEuropean Neuropsychopharmacology, 2007
- Citalopram Concentrations and Response in Obsessive-Compulsive DisorderCNS Drugs, 2004
- Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorderInternational Clinical Psychopharmacology, 2001
- Evidence-based pharmacotherapy of obsessive–compulsive disorderInternational Journal of Neuropsychopharmacology, 1999
- The Yale-Brown Obsessive Compulsive ScaleArchives of General Psychiatry, 1989
- The Epidemiology of Obsessive-Compulsive Disorder in Five US CommunitiesArchives of General Psychiatry, 1988
- An inventory for measuring clinical anxiety: Psychometric properties.Journal of Consulting and Clinical Psychology, 1988
- An Inventory for Measuring DepressionArchives of General Psychiatry, 1961
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960